EQS Group-News: Zur Rose Group AG / Key word(s): Quarterly / Interim Statement
Zur Rose Group starts 2020 with strong growth
- Significant revenue growth in all markets
- Draft law driving digitalisation ahead in Germany: e-prescriptions envisaged
- Ready for accelerated growth, courtesy of CHF 175 million convertible bond
The Zur Rose Group continued along the growth track in the first quarter of 2020, with revenue rising 15.9 per cent in local currency terms. Revenue amounts to CHF 426.6 million (including medpex sales). In Germany the Group grew by 15.5 per cent in local currency terms and generated revenue of CHF 263.6 million. In Switzerland Zur Rose boosted revenue by 14.2 per cent to CHF 151.2 million despite cuts in the cost of medicines. In the Europe segment, which currently comprises just Spain and France, the Zur Rose Group grew by 63.9 per cent in local currency terms. The segment contributed CHF 12.4 million to Group revenue.
Increased demand in the mail-order business
Germany: doctors' prescriptions to be electronic only from 2022
Financial flexibility for growth initiatives
CEO Walter Oberhänsli said of the challenges arising from the COVID-19 pandemic: "We are very proud of our employees, who are working to their limits throughout the Group every day to ensure our customers are supplied with the medicines they need as quickly as possible. Together, bricks and mortar and e-commerce pharmacies are seeing to it that elderly patients, often with multiple conditions, are as well protected as possible against the coronavirus - either by home deliveries or by mail-order."
Investors and analyst contact
Zur Rose Group
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and has around seven million active customers in core European markets.
With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.
The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.
|Company:||Zur Rose Group AG|
|Phone:||+41 52 724 08 14|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1022465|
|End of News||EQS Group News Service|